Plain-English translation of NCT05923333 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether a probiotic called Bifidobacterium infantis Rosell®-33, given to newborns during their first month of life, can help boost their immune systems. Babies born to mothers with HIV often have weaker immune systems and different gut bacteria than other babies. Researchers hope this medication will help their bodies fight infections and respond better to vaccines.
Babies born to mothers with HIV (who are not infected themselves) face extra health challenges and have altered gut bacteria that may weaken their immunity. This trial exists to test whether restoring beneficial bacteria early in life could improve these babies' immune health and overall wellbeing.
You likely qualify if…
You likely don't qualify if…
If your baby is enrolled, you will give them either the probiotic supplement or a placebo (inactive substance) once daily for the first 4 weeks of life, starting within the first few days after birth. Your baby will be followed for 36 weeks total, with regular visits where the research team will collect health information, samples, and check how your baby is growing and responding to vaccines. Neither you nor the research team will know which group your baby is in until the study ends.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Africa